Login to Your Account



Pharma: Clinic Roundup


Tuesday, October 15, 2013
Lurasidone, an atypical antipsychotic developed by Dainippon Sumitomo Pharma Co. Ltd., of Osaka, Japan, and marketed by its subsidiary Sunovion Pharmaceuticals Inc., of Marlborough, Mass., was the subject of five poster presentations at the 26th European College of Neuropsychopharmacology Congress in Barcelona, Spain.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription